516 related articles for article (PubMed ID: 33089365)
1. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
[TBL] [Abstract][Full Text] [Related]
2. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
3. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.
Molitor DCA; Boor P; Buness A; Schneider RK; Teichmann LL; Körber RM; Horvath GL; Koschmieder S; Gütgemann I
Ann Hematol; 2021 Jan; 100(1):97-104. PubMed ID: 33104881
[TBL] [Abstract][Full Text] [Related]
4. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
5. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
[TBL] [Abstract][Full Text] [Related]
6. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M
Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
[TBL] [Abstract][Full Text] [Related]
7. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.
Sangle N; Cook J; Perkins S; Teman CJ; Bahler D; Hickman K; Wilson A; Prchal J; Salama ME
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):663-8. PubMed ID: 24897074
[TBL] [Abstract][Full Text] [Related]
8. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
[TBL] [Abstract][Full Text] [Related]
9. CCN2/CTGF expression does not correlate with fibrosis in myeloproliferative neoplasms, consistent with noncanonical TGF-β signaling driving myelofibrosis.
Leguit RJ; Broekhuizen R; de Witte M; Raymakers RAP; Goldschmeding R
Virchows Arch; 2024 May; 484(5):837-845. PubMed ID: 38602559
[TBL] [Abstract][Full Text] [Related]
10. Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis.
Kapor S; Momčilović S; Kapor S; Mojsilović S; Radojković M; Apostolović M; Filipović B; Gotić M; Čokić V; Santibanez JF
Adv Exp Med Biol; 2023; 1408():273-290. PubMed ID: 37093433
[TBL] [Abstract][Full Text] [Related]
11. GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis.
Lally J; Boasman K; Brown L; Martinelli V; Cappuccio I; Sovani V; Marinaccio C; Crispino JD; Graham C; Rinaldi C
J Thromb Haemost; 2019 Jun; 17(6):896-900. PubMed ID: 30889303
[TBL] [Abstract][Full Text] [Related]
12. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
13. The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.
Slot S; van de Donk NWCJ; Otten RHJ; Boden BJH; Zijlstra J; Raijmakers PGHM; Zweegman S
Cancer Imaging; 2021 Apr; 21(1):36. PubMed ID: 33879266
[TBL] [Abstract][Full Text] [Related]
14. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
15. Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients.
Ruberti S; Bianchi E; Guglielmelli P; Rontauroli S; Barbieri G; Tavernari L; Fanelli T; Norfo R; Pennucci V; Fattori GC; Mannarelli C; Bartalucci N; Mora B; Elli L; Avanzini MA; Rossi C; Salmoiraghi S; Zini R; Salati S; Prudente Z; Rosti V; Passamonti F; Rambaldi A; Ferrari S; Tagliafico E; Vannucchi AM; Manfredini R
Leukemia; 2018 Feb; 32(2):438-449. PubMed ID: 28745329
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
[TBL] [Abstract][Full Text] [Related]
17. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation.
Khanlari M; Wang X; Loghavi S; Wang SA; Li S; Thakral B; Bueso-Ramos CE; Yin CC; Kanagal-Shamanna R; Khoury JD; Patel KP; Popat UR; Medeiros LJ; Konoplev S
Ann Diagn Pathol; 2022 Feb; 56():151860. PubMed ID: 34823075
[TBL] [Abstract][Full Text] [Related]
18. Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis.
Collinson RJ; Wilson L; Boey D; Ng ZY; Mirzai B; Chuah HS; Howman R; Grove CS; Malherbe JAJ; Leahy MF; Linden MD; Fuller KA; Erber WN; Guo BB
Platelets; 2024 Dec; 35(1):2304173. PubMed ID: 38303515
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
Fisher DAC; Fowles JS; Zhou A; Oh ST
Front Immunol; 2021; 12():683401. PubMed ID: 34140953
[TBL] [Abstract][Full Text] [Related]
20. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
